The more important practical problem is that no matter how the line is drawn, most biotechnological interventions that could be seen as problematic if used as enhancements will not need to be justified as enhancements in order to be developed and approved for clinical use. This is because most such interventions will also have legitimate therapeutic applications. Indeed, most biomedical tools with potential for enhancement uses will first emerge as therapeutic agents. For example, general cognitive enhancement interventions are likely to be approved for use only in patients with neurological diseases. However, to the extent that they are in high demand by individuals suffering the effects of normal aging, the risk of unapproved or “off-label” uses will be high (Whitehouse, et. al, 1997).